Eli Lilly’s only formal tie-up with Peptron remains the non-exclusive October 2024 research agreement granting evaluation rights to the ultrasonic spray-dried PLGA microsphere SmartDepot platform for sustained peptide release. Nearly two years later, no commercial licensing, technology-transfer, or manufacturing deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. Joint research continues across multiple candidates and the evaluation window has been extended, yet the short runway to the October 7 resolution date and absence of any recent progress announcements leave traders assigning an 87.5% probability that a binding commercial license will not materialize in time.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড13% সম্ভাবনা
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
13% সম্ভাবনা
$11,264 Vol.
$11,264 Vol.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s only formal tie-up with Peptron remains the non-exclusive October 2024 research agreement granting evaluation rights to the ultrasonic spray-dried PLGA microsphere SmartDepot platform for sustained peptide release. Nearly two years later, no commercial licensing, technology-transfer, or manufacturing deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. Joint research continues across multiple candidates and the evaluation window has been extended, yet the short runway to the October 7 resolution date and absence of any recent progress announcements leave traders assigning an 87.5% probability that a binding commercial license will not materialize in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 5, 2026, 8:02 PM ET
ভলিউম
$11,264শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s only formal tie-up with Peptron remains the non-exclusive October 2024 research agreement granting evaluation rights to the ultrasonic spray-dried PLGA microsphere SmartDepot platform for sustained peptide release. Nearly two years later, no commercial licensing, technology-transfer, or manufacturing deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. Joint research continues across multiple candidates and the evaluation window has been extended, yet the short runway to the October 7 resolution date and absence of any recent progress announcements leave traders assigning an 87.5% probability that a binding commercial license will not materialize in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$11,264শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s only formal tie-up with Peptron remains the non-exclusive October 2024 research agreement granting evaluation rights to the ultrasonic spray-dried PLGA microsphere SmartDepot platform for sustained peptide release. Nearly two years later, no commercial licensing, technology-transfer, or manufacturing deal has been disclosed, while Lilly separately partnered with Camurus in June 2026 for its competing FluidCrystal long-acting incretin technology. Joint research continues across multiple candidates and the evaluation window has been extended, yet the short runway to the October 7 resolution date and absence of any recent progress announcements leave traders assigning an 87.5% probability that a binding commercial license will not materialize in time.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা